Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adaptimmune Therapeutics plc ADAP

Healthcare Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include... see more

Recent & Breaking News (NDAQ:ADAP)

Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune's Cell Therapies

GlobeNewswire October 9, 2019

Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer

GlobeNewswire October 1, 2019

Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO

GlobeNewswire September 30, 2019

United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4

GlobeNewswire September 9, 2019

Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

GlobeNewswire August 27, 2019

New Executive Team Announced at Adaptimmune

GlobeNewswire August 1, 2019

Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update

GlobeNewswire August 1, 2019

Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019

GlobeNewswire July 29, 2019

Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS

GlobeNewswire July 25, 2019

Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center

GlobeNewswire July 22, 2019

Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE?A4 to Enhance Antitumor Responses

GlobeNewswire July 18, 2019

Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer

GlobeNewswire June 27, 2019

Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products

GlobeNewswire May 15, 2019

Adaptimmune Reports First Quarter 2019 Financial Results

GlobeNewswire May 6, 2019

Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors

GlobeNewswire May 6, 2019

Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting

GlobeNewswire May 2, 2019

Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019

GlobeNewswire May 1, 2019

Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting

GlobeNewswire April 18, 2019

Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting

GlobeNewswire April 2, 2019

Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire April 1, 2019